Lappaol F, an anticancer agent, inhibits YAP via transcriptional and post-translational regulation

References

• Amin A, Gali-Muhtasib H, Ocker M, Schneider-Stock R. 2009. Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci. 5(1):1–11.
   PubMedGoogle Scholar
• Amin SA, Adhikari N, Jha T, Gayen S. 2018. A review on camptothecin analogs with promising cytotoxic profile. Anticancer Agents Med Chem. 18(13):1796–1814.
   PubMed Web of Science ®Google Scholar
• Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. 2017. Paclitaxel: What has been done and the challenges remain ahead. Int J Pharm. 526(1-2):474–495.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW, Gragoudas E, Vavvas DG. 2014. The clinically used photosensitizer verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 124:67–73.
   PubMed Web of Science ®Google Scholar
• Cao JJ, Zhao XM, Wang DL, Chen KH, Sheng X, Li WB, Li MC, Liu WJ, He J. 2014. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis. Oncol Rep. 32(4):1594–1600.
   PubMed Web of Science ®Google Scholar
• Chan YS, Cheng LN, Wu JH, Chan E, Kwan YW, Lee SM, Leung GP, Yu PH, Chan SW. 2011. A review of the pharmacological effects of Arctium lappa (burdock). Inflammopharmacology. 19(5):245–254.
   PubMedGoogle Scholar
• Chen X, Gu W, Wang Q, Fu X, Wang Y, Xu X, Wen Y. 2018. C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC. Oncotarget. 9(1):668–679.
   PubMedGoogle Scholar
• He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al. 2015. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med. 7(11):1426–1449.
   PubMed Web of Science ®Google Scholar
• Jang W, Kim T, Koo JS, Kim SK, Lim DS. 2017. Mechanical cue-induced YAP instructs Skp2-dependent cell cycle exit and oncogenic signaling. Embo J. 36(17):2510–2528.
   PubMed Web of Science ®Google Scholar
• Kim HM, Jung WH, Koo JS. 2015. Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol. 8(9):11248–11257.
   PubMed Web of Science ®Google Scholar
• Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. 2012. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 109(37):E2441–E2450.
   PubMed Web of Science ®Google Scholar
• Li X, Liu Y, Zhang C, Niu Q, Wang H, Che C, Xie M, Zhou B, Xu Y, Zhang Q, et al. 2017. Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway. Oncotarget. 8(10):16356–16366.
   PubMedGoogle Scholar
• Liu Z, Zeng W, Wang S, Zhao X, Guo Y, Yu P, Yin X, Liu C, Huang T. 2017. A potential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycle progression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells. Am J Transl Res. 9(7):3212–3223.
   PubMed Web of Science ®Google Scholar
• Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S. 2018. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead. Bioorg Med Chem Lett. 28(17):2816–2826.
   PubMed Web of Science ®Google Scholar
• Meng Z, Lv Q, Lu J, Yao H, Lv X, Jiang F, Lu A, Zhang G. 2016. Prodrug strategies for paclitaxel. IJMS. 17(5):796.
   Google Scholar
• Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, et al. 2012. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene. 31(49):5117–5122.
   PubMed Web of Science ®Google Scholar
• Oku Y, Nishiya N, Shito T, Yamamoto R, Yamamoto Y, Oyama C, Uehara Y. 2015. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio. 5:542–549.
   PubMed Web of Science ®Google Scholar
• Park SY, Hong SS, Han XH, Hwang JS, Lee D, Ro JS, Hwang BY. 2007. Lignans from Arctium lappa and their inhibition of LPS-induced nitric oxide production. Chem Pharm Bull (Tokyo). 55(1):150–152.
   PubMed Web of Science ®Google Scholar
• Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H, Sun B, Yin D, Sun J, Song R, et al. 2015. YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 6(19):17206–17220.
   PubMedGoogle Scholar
• Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et al. 2012. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 151(7):1457–1473.
   PubMed Web of Science ®Google Scholar
• Sambandam SAT, Kasetti RB, Xue L, Dean DC, Lu Q, Li Q. 2015. 14-3-3σ regulates keratinocyte proliferation and differentiation by modulating Yap1 cellular localization. J Invest Dermatol. 135(6):1621–1628.
   PubMed Web of Science ®Google Scholar
• Schumacher B, Skwarczynska M, Rose R, Ottmann C. 2010. Structure of a 14-3-3σ-YAP phosphopeptide complex at 1.15 Å resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun. 66(Pt 9):978–984.
   PubMedGoogle Scholar
• Sharif GM, Wellstein A. 2015. Cell density regulates cancer metastasis via the Hippo pathway. Future Oncol. 11(24):3253–3260.
   PubMed Web of Science ®Google Scholar
• Sirikantaramas S, Asano T, Sudo H, Yamazaki M, Saito K. 2007. Camptothecin: Therapeutic potential and biotechnology. Curr Pharm Biotechnol. 8(4):196–202.
   PubMed Web of Science ®Google Scholar
• Song J, Xie LX, Zhang XY, Hu P, Long MF, Xiong F, Huang J, Ye XQ. 2018. Role of YAP in lung cancer resistance to cisplatin. Oncol Lett. 16(3):3949–3954.
   PubMed Web of Science ®Google Scholar
• Song Y, Li X, Liu Y, Hu Y, Yang R. 2019. Arctigenin improves lipid metabolism by regulating AMP-activated protein kinase and downstream signaling pathways. J Cell Biochem. 120(8):13275–13288.
   PubMed Web of Science ®Google Scholar
• Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. 2008. Expression of Yes-associated protein in common solid tumors. Hum Pathol. 39(11):1582–1589.
   PubMed Web of Science ®Google Scholar
• Su S, Cheng X, Wink M. 2015. Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells. Phytomedicine. 22(2):301–307.
   PubMed Web of Science ®Google Scholar
• Su S, Wink M. 2015. Natural lignans from Arctium lappa as antiaging agents in Caenorhabditis elegans. Phytochemistry. 117:340–350.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu K, Shen X, Jin W, Jiang L, Sheikh MS, Hu Y, Huang Y. 2014. Lappaol F, a novel anticancer agent isolated from plant Arctium lappa L. Mol Cancer Ther. 13(1):49–59.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Kasamatsu A, Yamatoji M, Nakashima D, Endo-Sakamoto Y, Koide N, Takahara T, Shimizu T, Iyoda M, Ogawara K, et al. 2017. TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase. Biochem Biophys Res Commun. 486(2):385–390.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. 2016. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res. 6(1):27–37.
   PubMed Web of Science ®Google Scholar
• Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, Zhu Q. 2013. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 8(6):e65539.
   PubMed Web of Science ®Google Scholar
• Wu L, Yang X. 2018. Targeting the Hippo pathway for breast cancer therapy. Cancers (Basel). 10(11):422.
   PubMed Web of Science ®Google Scholar
• Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M, Fan HY. 2014. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 9(3):e91770.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y, Dong J. 2013. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 73(22):6722–6733.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Hong W. 2008. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 13(3):188–192.
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 24(1):72–85.
   PubMed Web of Science ®Google Scholar
• Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al. 2007. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21(21):2747–2761.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Khanal P, Savage P, She YM, Cyr TD, Yang X. 2014. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway. Cancer Res. 74(16):4493–4503.
   PubMed Web of Science ®Google Scholar
• Zhu RJ, Shen XL, Dai LL, Ai XY, Tian RH, Tang R, Hu YJ. 2014. Total aglycones from Marsdenia tenacissima increases antitumor efficacy of paclitaxel in nude mice. Molecules. 19(9):13965–13975.
   PubMed Web of Science ®Google Scholar